This is a third blog critical of the use of references in Eat Rich Live Long
Ridker article 2017
In Jupiter, cholesterol efflux capacity was associated with incident CVD in individuals on potent statin therapy but not at baseline.
Cholesterol efflux capacity was moderately correlated with
1- HDL cholesterol, r= 0.39,
2-apolipoprotein A-I, r= 0.48,
3-HDL particle number, r= 0.39
Baseline HDL particle number was inversely associated with incident CVD (adjusted odds ratio per SD increment [OR/SD], 0.69; 95% confidence interval [CI], 0.56-0.86; P less than 0.001),
whereas no significant association was found for
1-baseline cholesterol efflux capacity (OR/SD, 0.89; 95% CI, 0.72-1.10; P=0.28),
2-HDL cholesterol (OR/SD, 0.82; 95% CI, 0.66-1.02; P=0.08), or
3-apolipoprotein A-I (OR/SD, 0.83; 95% CI, 0.67-1.03; P=0.08).
Twelve months of rosuvastatin (20 mg/day) did not change cholesterol efflux capacity (average percentage change -1.5%, 95% CI, -13.3 to +10.2; P=0.80), but increased
1-HDL cholesterol (+7.7%),
2- apolipoprotein A-I (+4.3%), and
3- HDL particle number (+5.2%).
On-statin cholesterol efflux capacity was inversely associated with incident CVD (OR/SD, 0.62; 95% CI, 0.42-0.92; P=0.02),
although HDL particle number again emerged as the strongest predictor (OR/SD, 0.51; 95% CI, 0.33-0.77; P less than 0.001).